Wojeck, Brian S.
Inzucchi, Silvio E.
Neeland, Ian J.
Mancuso, James P.
Frederich, Robert
Masiukiewicz, Urszula
Cater, Nilo B.
McGuire, Darren K.
Cannon, Christopher P.
Yaggi, Henry Klar
Funding for this research was provided by:
Merck Sharp and Dohme
Pfizer
Article History
Received: 1 February 2022
Revised: 1 February 2022
Accepted: 2 March 2022
First Online: 20 May 2022
Declarations
:
: B.S.W. declares no conflicts of interest. S.E.I. has participated on clinical trial executive/steering/publications committees and/or served as an adviser for Abbott, AstraZeneca, Boehringer Ingelheim, Esperion, Novo Nordisk, and VTV Therapeutics; has delivered lectures supported by AstraZeneca, Boehringer Ingelheim, and Merck; and has received support for attending meetings from AstraZeneca, Boehringer Ingelheim, and Novo Nordisk. I.J.N. has received a grant (directed to his institution) from the National Institutes of Health, consulting fees from Boehringer Ingelheim/Lilly Alliance, and Merck & Co., and has delivered lectures supported by Nestlé Health Sciences. H.K.Y. declares no conflicts of interest. D.K.M. has received consulting fees from AstraZeneca, Boehringer Ingelheim, Lexicon, Merck Sharp & Dohme, and Pfizer Inc. and has received payment for expert testimony from Kirkland & Ellis on behalf of Boehringer Ingelheim. C.P.C. has received research grants from Amgen, Better Therapeutics, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Janssen, Merck, Novo Nordisk, and Pfizer; fees from Aegerion/Amryt, Alnylam, Amarin, Amgen, Applied Therapeutics, Ascendia, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Janssen, Lexicon, Merck, Pfizer, Rhoshan, and Sanofi; and has served on Data and Safety Monitoring Boards for the Veteran’s Administration, Applied Therapeutics, and NovoNordisk. J.P.M., R.F., U.M., and N.B.C. are employees and shareholders of Pfizer Inc.